Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

Abstract Background We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant and dexamethasone in preventing chemotherapy-induc...

Full description

Bibliographic Details
Main Authors: Hisanori Shimizu, Kenichi Suzuki, Takeshi Uchikura, Daiki Tsuji, Takeharu Yamanaka, Hironobu Hashimoto, Koichi Goto, Reiko Matsui, Nobuhiko Seki, Toshikazu Shimada, Shunya Ikeda, Naoki Ikegami, Toshihiro Hama, Nobuyuki Yamamoto, Tadanori Sasaki
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Highly emetogenic chemotherapy
5-HT3 receptor antagonist
Palonosetron
Granisetron
Chemotherapy-induced nausea and vomiting
Cost-effectiveness
Online Access:http://link.springer.com/article/10.1186/s40780-018-0128-9

Internet

http://link.springer.com/article/10.1186/s40780-018-0128-9

Similar Items